Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

Persistent Asthma Clinical Trial

Official title:

Open Randomized Low Interventional Clinical Trial to Compare Efficiency in Control Symptoms Between Fluticasone Propionate/Formoterol K-haler (Medium Strength) vs High Strength ICS/LABA in the Treatment of Patients With Persistent Asthma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04271839
• Other study ID #: EffICIENCY
• Status: Withdrawn
• Phase: Phase 4
• Start date: June 11, 2020
• Est. completion date: May 2021

Study information

• Verified date: February 2020
• Source: Mundipharma Pharmaceuticals S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical trial to demonstrate whether, in patients with moderate asthma, to treat with IC / LABA a medium dose, but not controlled, to achieve a similar degree of control by making a progressive increase of that treatment (CI / LABA a high dose) versus switching to fluticasone / Formoterol K-Haler at medium dose, under conditions of usual clinical practice.

Description:

Asthma is a common chronic respiratory disease that affects about 300 million people worldwide. Although knowledge about asthma and its treatment has improved over the past decade, morbidity and mortality remain considerable.

Inhaled therapy is the treatment of choice in persistent asthma. Lower doses of drug are used that maximize the therapeutic effect and minimize side effects.

Inhaled therapy is administered primarily through inhalers. The goal is to deliver the maximum amount of medication to your therapeutic target in the lungs → lung deposit Each inhaler offers a different lung deposit figure (data in ideal conditions). However, asthma control also depends on other factors (inhalation technique, adhesion, asthma severity, drug dose, etc.).

The K-haler® inhaler device has obtained a high lung deposit (≈45% of the emitted dose) and an easy-to-use device.

In general, the rest of the CI / LABA inhalers offer lower deposit figures. They are between ≈10-40% of the dose.

Taking into account all that has been said in the introduction section, it has been decided to design this low-intervention clinical trial, to verify whether, those technical benefits of K-haler®, control asthma in a similar way using lower doses of IC .

If these hypotheses were confirmed, it would allow for an effective therapeutic option in the control of asthma using a lower therapeutic dose, saving IC and a lower probability of producing side effects.

Demonstrate whether, in patients with moderate asthma, to treat with IC / LABA a medium dose, but not controlled, to achieve a similar degree of control by making a progressive increase of that treatment (CI / LABA a high dose) versus switching to fluticasone / Formoterol K-Haler at medium dose, under conditions of usual clinical practice.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2021
• Est. primary completion date: May 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age > or = 18 years.

2. Objective diagnosis of asthma (according to GEMA 4.4) (Guía Española de Manejo del Asma)

3. Patients in treatment with a stable average dose of IC in a fixed dose combination of IC / LABA *, without changes in the dose or in the inhaler, during the 3 months prior to inclusion, in accordance with its approved indication and Data sheet. * Except for K-Haler®

4. Patients who need, according to medical criteria, a dose increase of IC in the current fixed IC / LABA combination.

5. Inhalation technique: no critical errors with the current inhaler after training.

6. Patient with uncontrolled asthma with an ACQ> 0.75 points (partially controlled or poorly controlled asthma).

7. Informed consent in signed writing.

Exclusion Criteria:

1. Diagnosis of other respiratory pathology other than asthma (clinically relevant bronchiectasis, pulmonary fibrosis, COPD (Chronic Obstructive Pulmonary Disease) and others at the discretion of the investigator).

2. =1 severe exacerbation (require the use of systemic corticosteroids - oral, suspension or injection - or increasing the dose of maintenance therapy for at least 3 days, or hospitalization or emergency room visits due to asthma requiring the use of systemic corticosteroids) in the last month or =3 in the previous 12 months.

3. Pregnancy or probability of being pregnant during the study.

4. Patient who, at the discretion of the investigator, does not have the capacity to complete the questionnaires.

5. Patient under treatment with monoclonal antibodies during the study.

6. Patient in another clinical trial.

7. Patient who has received an experimental drug in the last 30 days (12 weeks if it is a systemic steroid).

8. Do not use a MART (MAintenance and Reliever Therapy) strategy within 3 months prior to inclusion or during the trial

9. Patient in IC / LABA treatment according to MART strategy (Maintenance and Rescue).

10. Any contraindication expressed in the CI / LABA data sheet used.

11. Patient with poor adherence (TAI-10 = 45)

12. Patients using an inhalation chamber

13. Patients with an index of Packages / year> 10

Related Conditions & MeSH terms

• Asthma
• Persistent Asthma

Intervention

Combination Product:
• fluticasone/formoterol k-haler (medium strength)
2 inhalations every 12 hours
• Standard of care (ICs/LABA high strength)
Depend of the ICs/LABA combination

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Mundipharma Pharmaceuticals S.L.	Alpha Bioresearch S.L., Dynamic Solutions

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Control of asthma	The control of asthma in patients with persistent asthma will be measured by scoring the ACQ-7 questionnaire (Asthma Control Questionnaire): Well controlled: = 0.75, Partially controlled: from 0.75 to 1.50, Poorly controlled:> 1.50	24 weeks
Secondary	Degree of asthma control according to GINA (Global Initiative for Asthma) questionnaire of four questions	Well Controlled (negative answer in the 4 questions), Partially controlled (affirmative answer in 1 or 2 of the answers), Uncontrolled (affirmative answer in 3 or 4 of the answers)	24 weeks
Secondary	Success in asthma treatment	Defined as asthma patients who progress from poorly controlled asthma to partially or well controlled asthma, or from partially controlled asthma to controlled asthma, with no change in baseline asthma treatment after randomization; Measured by scoring the ACQ-7 questionnaire: Well controlled: = 0.75, Partially controlled: from 0.75 to 1.50, Poorly controlled:> 1.50	24 weeks
Secondary	Adherence to treatment	Through TAI-12 questionnaire (Erratic Total Score 1-5 items, Deliberate Total Score 6-10 items, Unconscious Total Score 11-12 items) And through electronic prescription (if the amount of medication withdrawn in pharmacy matches that prescribed by the doctor)	24 weeks
Secondary	Critical errors with the inhaler	Number of critical errors	24 weeks
Secondary	Patient satisfaction with the inhaler	Through the FSI-10 (Feeling of Satisfaction with Inhaler) questionnaire (It consists of 10 questions, each with 5 response options on a 5-step Likert scale ("a lot", "a lot", "something", "little" and "very little") scored, respectively, from 5 to 1 (score total: 50). It evaluates the degree of patient satisfaction with the inhalation device and includes items related to comfort, difficulty, transportability and use.)	24 weeks
Secondary	Quality of Life of the patient	Through Mini-AQLQ (Mini Asthma Quality of Life Questionnaire) questionnaire: This 15-item questionnaire is a short version of the complete 32-item questionnaire, but constitutes of the same 4 domains: symptoms, environment, emotions, activities, and covering a 2 week period. Scores range from 0-6 (lower is worse). The mini-AQLQ score is calculated as the average of domain items. The minimum clinically important difference is 0.5.; This version has been developed to meet the needs of long-term monitoring, where efficiency may take precedent over precision of measurement	24 weeks
Secondary	Severe asthmatic exacerbations	Number severe asthmatic exacerbations (require the use of systemic corticosteroids - oral, suspension or injection - or the increase in the dose of maintenance therapy for at least 3 days, or hospitalization or visits to the emergency room due to asthma that requires the use of systemic corticosteroids)	24 weeks
Secondary	Forced Expiratory Volume at first second (FEV1)	Using the FEV1 score of the patient's spirometry	24 weeks
Secondary	Forced Vital Capacity (FVC)	Using the FVC score of the patient's spirometry	24 weeks
Secondary	FEV1 / FVC ratio	Using the FEV1 and FVC score of the patient's spirometry	24 weeks
Secondary	Safety of the drug in investigation.	Type and incidence of adverse reactions	24 weeks